With 72 active trials, it’s only a matter of time
23rd April 2020 - 0 comments
As of April 19, 2020, the number of active trials to test potential therapeutic agents against COVID-19 is at 72, with another 122 therapeutic agent development programs currently in their planning stages.
With the help from the FDA’s Coronavirus Treatment Acceleration Program (CTAP), trials such as these that measure the efficacy and safety of therapeutic agents are given extra support, so that treatments can be provided as quickly as possible to patients in need.
Pluristem Therapeutics Inc. is one example of a company that is benefitting from CTAP. The company has recently released news of successfully treating six patients in Israel suffering from severe COVID-19 complications, including acute respiratory failures. These positive results have now led to Pluristem starting clinical trials in the US, having already treated a patient that suffered from acute respiratory distress syndrome (ARDS) and had been in ICU three weeks prior to treatment. The treatment involves Pluristem’s PLX cell therapy – its immunomodulatory properties aim to help prevent, or even reverse, the overactivation of the immune system in response to COVID-19.
With success stories such as these happening across the world, it’s only a matter of time before effective treatments are widely available.